About Dan

This author has not yet filled in any details.
So far Dan has created 17 blog entries.

Sorrento Announces the Closing of Its Acquisition of SmartPharm to Build Next Generation G-MAB-Encoded Plasmid DNA For Cost-Efficient and In Vivo Production of Antibody Therapeutics in Patients

Sorrento Announces the Closing of Its Acquisition of SmartPharm to Build Next Generation G-MAB-Encoded Plasmid DNA For Cost-Efficient and In Vivo Production of Antibody Therapeutics in Patients September 2, 2020 at 9:00 AM EDT Download PDF SAN DIEGO and BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: [...]

By |2020-09-10T12:50:17-04:00September 10th, 2020|Press Releases|0 Comments

Sorrento Enters Into Merger Agreement to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies to Treat COVID-19 and Cancer Therapeutics

Sorrento Enters Into Merger Agreement to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies to Treat COVID-19 and Cancer Therapeutics The combination of SmartPharm’s Gene Mab™ gene-encoded in vivo expression system and Sorrento’s SARS-CoV-2 neutralizing antibodies may potentially provide longer-acting, single injection protection against COVID-19. Beyond COVID-19, [...]

By |2020-08-20T17:30:55-04:00August 20th, 2020|Press Releases|0 Comments

Sorrento Enters Into Letter Of Intent To Acquire SmartPharm And Develop Pipeline Of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies To Treat COVID-19 and Cancer Therapeutics

Sorrento Enters Into Letter Of Intent To Acquire SmartPharm And Develop Pipeline Of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies To Treat COVID-19 and Cancer Therapeutics The combination of SmartPharm's Gene Mab™ gene-encoded in vivo expression system and Sorrento's SARS-CoV-2 neutralizing antibodies may potentially provide longer-acting, single injection protection against COVID-19. The [...]

By |2020-07-24T18:47:45-04:00July 24th, 2020|Press Releases|0 Comments

Dr. Trevejo paper in Nature Biotechnology highlights critical considerations in the race to develop COVID-19 vaccines and antibody countermeasures

Dr. Trevejo paper in Nature Biotechnology highlights critical considerations in the race to develop COVID-19 vaccines and antibody countermeasures.In this important race to develop protections and treatments, key facets of the biology of SARS-CoV-2 are critical for consideration. A recent Nature Biotechnology publication written in collaboration with HelixNano and Dr. George Church of the Harvard, Wyss [...]

By |2020-06-09T14:52:12-04:00June 5th, 2020|News|0 Comments

Dr. Trevejo discusses the importance of diversity in clinical trials and the non-viral gene therapy we are developing against COVID-19

Watch as our CEO Dr. Trevejo discusses the importance of diversity in clinical trials and the non-viral gene therapy we are developing to treat infection with Coronavirus. Watch now on CityLine.

By |2020-03-26T11:22:04-04:00March 26th, 2020|Interview|0 Comments

Sorrento Therapeutics and SmartPharm Therapeutics Announce Intention to Collaborate to Develop Novel Gene-Encoded Antibody Vaccine Intended for COVID-19

For Immediate Release March 23, 2020     SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19 Collaboration to leverage synergies between Monoclonal Antibody and Non-Viral Gene Delivery Platforms SAN DIEGO and BOSTON, March 23, 2020 /GlobeNewswire/ -- In response to the government call for rapidly deployable countermeasures, [...]

By |2020-03-23T10:00:18-04:00March 23rd, 2020|Press Releases|0 Comments

SmartPharm Therapeutics Appoints John T. Potts, MD, DSc, to Board of Directors

CAMBRIDGE, Mass., Oct. 21, 2019 /PRNewswire/ -- SmartPharm Therapeutics, a preclinical-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced the appointment of John T. Potts, MD, DSc, to its Board of Directors. Dr. Potts' distinguished, five-decade career in healthcare and the life sciences spans medical [...]

By |2019-10-21T13:37:57-04:00October 21st, 2019|Press Releases|0 Comments

SmartPharm Therapeutics Announces Presentation at the 2019 BIO Investor Forum

SmartPharm Therapeutics Announces Presentation at the 2019 BIO Investor Forum CAMBRIDGE, Mass., Oct. 16, 2019 /PRNewswire/ -- SmartPharm Therapeutics, a preclinical-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced that José Trevejo, MD, PhD, Chief Executive Officer, will present at the 2019 BIO [...]

By |2019-11-01T14:23:12-04:00October 16th, 2019|Press Releases|0 Comments
Go to Top